Health Care & Life Sciences » Pharmaceuticals | Mitsubishi Tanabe Pharma Corp.

Mitsubishi Tanabe Pharma Corp.

Mitsubishi Tanabe Pharma Corp. ADR
Stock Exchange Other OTC
EPS
 $0.6
Market Cap
 $6.48 B
Shares Outstanding
 561.42 M
Public Float
 -
Mitsubishi Tanabe Pharma Corp.
Stock Exchange Frankfurt Stock Exchange
EPS
 -
Market Cap
 -
Shares Outstanding
 561.42 M
Public Float
 -
Mitsubishi Tanabe Pharma Corp.
Stock Exchange Tokyo Stock Exchange
EPS
 JPY66.64
Market Cap
 JPY702.66 B
Shares Outstanding
 561.42 M
Public Float
 220.14 M

Profile

Address
3-2-10 Dosho-machi
Osaka Osaka 541
Japan
Employees -
Website http://www.mt-pharma.co.jp
Updated 07/08/2019
Mitsubishi Tanabe Pharma Corp. engages in the research, development, manufacture, and sale of pharmaceutical products. Its products include Remicade, Ceredist, Talion, Kremezin, Maintate, Simponi, Lexapro, Tenelia, Tetrabik, and Imusera. The company operates through Pharmaceuticals segment.

Financials

View All
Created with Highcharts 5.0.14Mitsubishi Tanabe Pharma Corp.Net Income. Fiscal year is April-March. All values JPY Millions.45 39345 39339 50239 50259 30659 30671 26371 26357 96357 96337 37237 372201420152016201720182019020k40k60k80k
Created with Highcharts 5.0.14Mitsubishi Tanabe Pharma Corp.Sales/Revenue. Fiscal year is April-March. All values JPY Millions.412 675412 675415 124415 124425 764425 764423 977423 977433 855433 855424 767424 7672014201520162017201820190100k200k300k400k500k

Masayuki Mitsuka
President, CEO & Representative Director
Eizou Tabaru
Director, General Manager-Finance & Accounting
View All

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.